Patents Assigned to Hoffmann-La Roche Inc.
  • Patent number: 11655243
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1-R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: May 23, 2023
    Assignees: HOFFMANN-LA ROCHE INC., EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
    Inventors: Simon M. Ametamey, Kenneth Atz, Luca Gobbi, Uwe Grether, Wolfgang Guba, Julian Kretz
  • Publication number: 20230149395
    Abstract: Provided herein are methods of treating Relapsing Multiple Sclerosis (RMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 1, 2021
    Publication date: May 18, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Hideki GARREN, Edmond Huatung TENG, Aurelien VIACCOZ, Hans-Christian VON BUEDINGEN
  • Publication number: 20230151424
    Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator
    Type: Application
    Filed: June 16, 2022
    Publication date: May 18, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marie-Pierre Dube, Jean-Claude Tardif
  • Publication number: 20230154626
    Abstract: Systems and methods described herein improve outcomes of subjects with lymphoma. Subjects with lymphoma may be able to avoid conventional treatments that have a high probability of leading to an adverse effect in the subject. Systems and methods allow for a more accurate prediction of subjects who cannot tolerate a particular treatment. Methods may include accessing an input data set that includes multiple input data values pertaining to a particular subject with lymphoma. The method may further include inputting the input data set into a machine-learning model to generate a score corresponding to the degree to which the particular subject will tolerate a particular treatment. The method may include outputting a prediction of the tolerance of the particular subject to the particular treatment using the generated score.
    Type: Application
    Filed: January 19, 2023
    Publication date: May 18, 2023
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Tina Geritz Nielsen, Joseph Nathaniel Paulson, Daniel Jay Schneider, Edward Jean Bataillard, Carl Wilson Harris, III, Carsten Henneges, Yoonha Choi
  • Publication number: 20230150995
    Abstract: The invention provides novel compounds having the general formula I wherein R and X are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: January 20, 2023
    Publication date: May 18, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido GALLEY, Patrick SCHNIDER
  • Publication number: 20230143310
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: June 30, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Publication number: 20230141600
    Abstract: The invention provides novel imidazopyrazine derivatives having the general formula (I), wherein Rx and R3 to R5 are as described herein: or pharmaceutically acceptable salts thereof. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: December 6, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zhanling CHENG, Christian KRAMER, Christian LERNER, Yongqiang LIU, Matthias NETTEKOVEN, Philippe PFLIEGER, Sébastien SCHMITT, Theodor STOLL, Jianhua WANG, Yongguang WANG, Song YANG, Chengang ZHOU
  • Publication number: 20230144399
    Abstract: The present invention provides novel compounds having the general formula: wherein R1 to R11 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: December 14, 2018
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Song FENG, Zongxing QIU, Guolong WU, Dongdong CHEN, Chao LI
  • Publication number: 20230141603
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R3, R4, R5 and X are as described herein, compositions including the compounds and methods of using the compounds for treatment of CNS disorders.
    Type: Application
    Filed: October 18, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Frédéric KNOFLACH, Andreas KOBLET, Eoin Cornelius O'CONNOR, Andres Miguel OLIVARES MORALES, Valerie RUNTZ-SCHMITT, Jaclyn WAMSTEEKER CUSULIN, Nicolas ZORN
  • Publication number: 20230141403
    Abstract: The invention provides novel imidazopyrazine derivatives having the general formula (I), or pharmaceutically acceptable salts thereof, wherein X, m, n, and R1 to R3 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: December 6, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zhanling CHENG, Xingchun HAN, Christian KRAMER, Holger KUEHNE, Christian LERNER, Mingming LI, Matthias NETTEKOVEN, Theodor STOLL, Min WANG, Song YANG
  • Publication number: 20230142171
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I) or (II), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: October 4, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Giuseppe CECERE, Luca GOBBI, Maria-Clemencia HERNANDEZ, Roland HUMM, Andrés Miguel OLIVARES MORALES, Angélique PATINY-ADAM, Valerie RUNTZ-SCHMITT, Christian SCHNIDER
  • Publication number: 20230133845
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: July 14, 2022
    Publication date: May 4, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mathis BRAENDLIN, Sandra Marie Joseph GRALL-ULSEMER, Xingchun HAN, Christian LERNER, Mingming LI, Yongqiang LIU, Sébastien SCHMITT, Jianhua WANG, Yongguang WANG, Min WANG, Song YANG, Chengang ZHOU
  • Publication number: 20230134606
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: June 30, 2022
    Publication date: May 4, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • Publication number: 20230136326
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.
    Type: Application
    Filed: September 28, 2022
    Publication date: May 4, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Bjoern BARTELS, Giuseppe CECERE, Guido GALLEY, Luca GOBBI, Maria-Clemencia HERNANDEZ, Andreas KOBLET, Andrés Miguel OLIVARES MORALES, Angélique PATINY-ADAM, Valerie RUNTZ-SCHMITT
  • Publication number: 20230135093
    Abstract: The invention provides compounds having the general formula (I) or (II) wherein R1, R2, R3, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 11, 2022
    Publication date: May 4, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Guillaume DÉCORET, Katrin GROEBKE ZBINDEN, Maria-Clemencia HERNANDEZ, Henner KNUST, Andreas KOBLET, Andres Miguel OLIVARES MORALES, Emmanuel PINARD, Valerie RUNTZ-SCHMITT
  • Patent number: 11639394
    Abstract: The invention relates to bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to epithelial cell adhesion molecule (EpCAM), and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: May 2, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sandra Grau-Richards, Christian Klein, Pablo Umaña, Maria Amann, Laurene Pousse
  • Publication number: 20230131782
    Abstract: Herein is reported a method for determining the epitope of an antibody specifically binding to a therapeutic antibody comprising the steps of a) incubating a sample, which comprises serum and the antibody specifically binding to a therapeutic antibody, separately with i) at least a Fab fragment of the therapeutic antibody, and ii) at least a Fab fragments of the therapeutic antibody in which the HVRs forming a paratope have been replaced with germline sequences, and detecting the binding or non-binding of the antibody specifically binding to a therapeutic antibody to the at least a Fab fragment in any of i) to ii), and b) determining the epitope of the antibody specifically binding to a therapeutic antibody to be in the at least one HVR that has been replaced in ii) if binding is detected in i) and non-binding is detected in ii).
    Type: Application
    Filed: June 30, 2022
    Publication date: April 27, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roland BECKMANN, Ekkehard MOESSNER, Kay-Gunnar STUBENRAUCH
  • Publication number: 20230129340
    Abstract: Herein are provided a method for producing a multispecific antibody comprising the steps of providing a mammalian cell expressing the antibody, transfecting said mammalian cell with an expression vector comprising an expression cassette encoding a polypeptide of the antibody that has a domain crossover, cultivating the transfected cell and recovering the antibody from the cell or the cultivation medium and thereby producing the multispecific antibody.
    Type: Application
    Filed: May 25, 2022
    Publication date: April 27, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan SEEBER, Ulrich GOEPFERT, Andrea OSTERLEHNER, Hubert KETTENBERGER, Wolfgang PAUL
  • Publication number: 20230123268
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3 and n are as defined herein, compositions including methods of making the compounds and using the compounds as ATX inhibitors.
    Type: Application
    Filed: December 7, 2022
    Publication date: April 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Angélica BEURIER, Luke GREEN, Christian KRAMER, Dmitry MAZUNIN, Emmanuel PINARD, Hasane RATNI
  • Patent number: D984469
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: April 25, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Kevin Adam Stewart